Presenter: Juan Mo. Learning objectives What is gene therapy? What is a Dox-regulatable system and how can gene expression be regulated by Dox? What is.

Slides:

Advertisements

Similar presentations

The Scotopic ERG Response A dim flash of light below the sensitivity threshold for cone photoreceptors stimulates only the rods in a dark adapted eye.

Advertisements

UCL Institute of Ophthalmology Department of Genetics

By Jawad Braick.  Macular degeneration is progressive loss of vision to the point of legal blindness due to damage to the macula, the part of the eye.

VIRAL VECTORS IN GENE THERAPY Gene Therapy The introduction of nucleic acids into cells for the purpose of altering the course of medical condition or.

Applications of ERG, mfERG & EOG

How the eye sees Last time Anatomy of the eye Cells in the retina Rods and cones Visual receptors This time Visual receptors Visual transduction 1.

Viruses and Gene Therapy

GENE THERAPY. In humans Cancer 69% General concerns The Food and Drug Administration (FDA) has not yet approved any human gene therapy product for sale.

Cancer Gene Therapy …Using Tumor Suppressor Genes.

Ryan Smith October 20,  Rare inherited eye disease (1 in 80,000)  Symptoms first occur in early infancy ◦ Irregular behavior, nystagmus  Progresses.

Gene therapy for eye disease UCL Institute of Ophthalmology Department of Genetics An experimental technique that uses the delivery of genetic material.

Antibiotics Bio February 2010 Ethan Richman Ben Kwak Ampicillin, Tetracyclin, and Chloramphenicol.

1 Testing sensory visual function. 2 types: 1) psychophysical tests 2) electrophysical tests.

Viruses are used for gene therapy

Stem Cell KSU. Stem Cell – Definition A cell that has the ability to continuously divide and differentiate (develop) into various other kind(s) of cells/tissues.

Presented by Juan Mo. Study Questions Why zebrafish transgenetic lines are very important for studying photoreceptor degeneration? The synapses in inner.

2) Vision The Special Senses 13 th edition Chapter 17 Pages th edition Chapter 17 Pages

Dr. Ayesha Abdullah Learning outcomes By the end of this lecture the students would be able to; Correlate the structural organization of the.

Gene Transfer for Neovascular Age- Related Macular Degeneration Peter A. Campochiaro The Wilmer Eye Institute The Johns Hopkins University School of Medicine.

Midterm Marks posted by next Monday Today - Vision Structure / anatomy of eyes Photochemistry of pigment molecules Transduction of light energy to electrical.

Psychology 210 Lecture 4 Kevin R Smith. Vision Sensory System –The eye –Exactly what we sense from our environment Perceptual System –The brain –How we.

Optical Coherence Tomography (OCT) Gella Laxmi 2009PHXF013P.

Gene Therapy By: Chris Smith and Darran Prewitt. What is gene therapy? Why is it used? Gene therapy = Introduction of normal genes into cells that contain.

Vitamin A & Visual Cycle

Gene Therapy in Retinitis Pigmentosa (RP) Henry J Kaplan, MD Evans Professor of Ophthalmology Chair, Department of Ophthalmology & Visual Sciences Director,

Fundamentals of Sensation and Perception LIGHT AND THE EYES ERIK CHEVRIER NOVEMBER 9, 2015.

Electroretinogram: An electrical diagnostic test of retinal function in situ n Electro -part –Currents, wires, voltage, resistance n Retino - part –Cell.

AAV-mediated Gene Therapy Restores Cone Function In A Rat With An M-cone Opsin Deficiency, A Model For Blue Cone Monochromacy Purpose: Using an AAV vector.

In most gene therapy studies, a "normal" gene is inserted into the genome to replace an "abnormal," disease-causing gene. A carrier molecule called a.

Gene Therapy (II) “Viral Gene Transfer Methods” Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:

Gene Therapy Mostafa A. Askar NCRRT By M.Sc. In Molecular Biology

Tet-Off® and Tet-On® Gene Expression Systems

Daisuke Kawata, Zetang Wu

INTRAVITREAL INJECTION OF

Gene Therapy: Molecular Biology

From: Deficiency of SHP-1 Protein-Tyrosine Phosphatase in “Viable Motheaten” Mice Results in Retinal Degeneration Invest. Ophthalmol. Vis. Sci ;47(3):

Volume 3, Issue 5, Pages (May 2001)

Invest. Ophthalmol. Vis. Sci ;58(2): doi: /iovs Figure Legend:

Volume 8, Issue 2, Pages (August 2003)

Volume 140, Issue 2, Pages e2 (February 2011)

Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward

Vision Science: Can Rhodopsin Cure Blindness?

Volume 16, Issue 3, Pages (March 2008)

Volume 12, Issue 6, Pages (December 2005)

Volume 11, Issue 6, Pages (June 2005)

Vision Science: Can Rhodopsin Cure Blindness?

Volume 22, Issue 2, Pages (February 2014)

Volume 29, Issue 3, Pages (March 2001)

Molecular Therapy - Methods & Clinical Development

Volume 25, Issue 1, Pages (January 2017)

Volume 4, Issue 6, Pages (December 2001)

Volume 19, Issue 2, Pages (February 2011)

Volume 12, Issue 2, Pages (August 2005)

Volume 140, Issue 2, Pages e2 (February 2011)

(case 6) (A) Fundus photography showing subtle discrete areas of RPE atrophy (green areas). (case 6) (A) Fundus photography showing subtle discrete areas.

Volume 4, Issue 5, Pages (November 2001)

Spatially and Temporally Regulated NRF2 Gene Therapy Using Mcp-1 Promoter in Retinal Ganglion Cell Injury Kosuke Fujita, Koji M. Nishiguchi, Yukihiro.

Molecular Therapy - Methods & Clinical Development

Volume 23, Issue 2, Pages (February 2015)

Improved Retinal Transduction In Vivo and Photoreceptor-specific Transgene Expression Using Adenovirus Vectors With Modified Penton Base Siobhan M Cashman,

Molecular Therapy - Methods & Clinical Development

Volume 17, Issue 12, Pages (December 2009)

Volume 8, Issue 2, Pages (August 2003)

Volume 22, Issue 9, Pages (September 2014)

J.M.I. Malik, Z. Shevtsova, M. Bähr, S. Kügler Molecular Therapy

Volume 25, Issue 4, Pages (April 2017)

Volume 9, Issue 2, Pages (February 2004)

Volume 13, Issue 5, Pages (May 2006)

Presentation transcript:

Presenter: Juan Mo

Learning objectives What is gene therapy? What is a Dox-regulatable system and how can gene expression be regulated by Dox? What is the difference between TetON and TetOFF? What is the role of RPE65? What is electroretinography (ERG)?

Introduction Gene therapy: the use of DNA as a pharmaceutical agent to treat disease. Parameters when choosing a gene therapy vector: (1) size limitations for insertion of transgenes, (2) purity and titer of the vector, (3) transduction efficiency, (4) ability to infect dividing and/or quiescent cells, (5) long-term expression of transgenes, (6) integration into the host genome, (7) the need for cell-type specificity or targeted delivery, (8) vector-associated toxicity and immunogenicity.

Virus Vector Adenovirus Adeno-associated virus Herpes simplex virus type 1 retrovirus

Regulatory System Doxycycline: is a member of the tetracycline antibiotics group. Doxycycline is used in "Tet-on" and "Tet-off" tetracycline-controlled transcriptional activation to regulate transgene expression in organisms and cell cultures. TRE: tetracycline response element tTA (Tet-off) or rtTA (Tet-on) : Tet-controlled transcriptional activator

Tet-OFF Regulatable Switch tTA (Tet-off) or rtTA (Tet-on) : Tet-controlled transcriptional activator TRE: tetracycline response element

Tet-ON Regulatable Switch tTA (Tet-off) or rtTA (Tet-on) : Tet-controlled transcriptional activator TRE: tetracycline response element

RPE65: The retinal pigment epithelium-specific 65 kDa protein is located in the retinal pigment epithelium and is involved in the conversion of all-trans retinyl ester to 11-cis retinol during phototransduction, which is then used in visual pigment regeneration in photoreceptor cells.

The ability of the Dox-regulatable system (Tet-OFF and Tet-ON) to regulate retinal function in RPE65-deficient dogs??

Results and Methods cDNA promoter transactivator cDNA transactivator promoter A1 to A3 A4 and A5 A6

Subretinal Injection -injection-gene-therapy-vectors-stem-cells- perinatal-mouse

AAV2/4TetOff.rpe65 (A2) CT6mpi AAV2/4TetOn.rpe65 (A4) CT 6mpi AAV2/4CMV.rpe65 (A6) CT6mpi Zone of the bleb OCT scanning path Retinal vessel Fundus photography Optical coherence tomography (OCT) image

immunogenicity AAV2/4TetOff.rpe65 (A2) AAV2/4TetOn.rpe65 (A4) AAV2/4CMV.rpe65 (A6) Mac: macaque, positive control

Electroretinography (ERG) measures the electrical responses of various cell types in the retina, including the photoreceptors (rods and cones), inner retinal cells (bipolar and amacrine cells), and the ganglion cells. If a flash ERG is performed on a dark-adapted eye, the response is primarily from the rod system. Flash ERGs performed on a light-adapted eye will reflect the activity of the cone system. Sufficiently bright flashes will elicit ERGs containing an a-wave (initial negative deflection) followed by a b-wave (positive deflection).

Sibling of RP patientRP patient

Left eyeRight eye

ERG Recording of TetOff Vector Treated Dogs

AAV2/4TetOff.rpe65 in RPE65-deficient dogs A1: Volume: 600ul A2: Volume: 350ul A3: Volume: 590ul untreated eye treated eye

ERG Recording of TetOn Vector Treated Dogs

AAV2/4TetOn.rpe65 in RPE65-deficient dogs A4: Volume: 540ul A5: Volume: 460ul untreated eye treated eye

Evaluation of Visual Function of A6, 3mpi and 6mpi

Evaluation of Visual Function of A1, 11mpi, ON2

Conclusion RPE65-deficient dogs treated with Dox- regulatable AAV vectors displayed retinal function recovery, but not rescue of vision. Injection of constitutive vectors in RPE65- deficient dogs showed improvement of vision when the amplitude of the dark- adapted b-wave was above 60  V.

Questions What is gene therapy? What is Dox-regulatable system? What is the difference between TetON and TetOFF? What is the role of RPE65? What is electroretinography (ERG)?

How might one resolve the problem these authors encountered in improving vision in RPE65-deficient dogs?